This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. NNVC, TAOX, ETHZ, IBIO, NBY, MTNB, AEON, NRBO, AEZS, and CPHIShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include NanoViricides (NNVC), Synaptogenix (TAOX), Flag Ship Acquisition (ETHZ), iBio (IBIO), NovaBay Pharmaceuticals (NBY), Matinas Biopharma (MTNB), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), Aeterna Zentaris (AEZS), and China Pharma (CPHI). RXi Pharmaceuticals vs. Its Competitors NanoViricides Synaptogenix Flag Ship Acquisition iBio NovaBay Pharmaceuticals Matinas Biopharma AEON Biopharma NeuroBo Pharmaceuticals Aeterna Zentaris China Pharma RXi Pharmaceuticals (NASDAQ:RXII) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Which has more volatility & risk, RXII or NNVC? RXi Pharmaceuticals has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Is RXII or NNVC more profitable? NanoViricides has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. NanoViricides' return on equity of -87.90% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RXi Pharmaceuticals-4,990.20% -412.15% -179.54% NanoViricides N/A -87.90%-78.69% Do institutionals & insiders have more ownership in RXII or NNVC? 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 1.0% of RXi Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer RXII or NNVC? In the previous week, NanoViricides had 3 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 3 mentions for NanoViricides and 0 mentions for RXi Pharmaceuticals. RXi Pharmaceuticals' average media sentiment score of 0.00 beat NanoViricides' score of -0.05 indicating that RXi Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment RXi Pharmaceuticals Neutral NanoViricides Neutral Which has preferable earnings & valuation, RXII or NNVC? NanoViricides has lower revenue, but higher earnings than RXi Pharmaceuticals. NanoViricides is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRXi Pharmaceuticals$10K954.84-$12.45M-$4.20-0.52NanoViricidesN/AN/A-$8.29M-$0.70-2.07 SummaryNanoViricides beats RXi Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.55M$934.71M$5.87B$10.14BDividend YieldN/A4.84%5.68%4.59%P/E Ratio-0.521.1074.5225.93Price / Sales954.8426.70548.33126.97Price / CashN/A19.5637.5660.44Price / Book2.836.6912.166.29Net Income-$12.45M-$4.50M$3.28B$270.77M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.18-6.0%N/A-16.8%$9.55M$10K-0.52N/AGap DownNNVCNanoViricides0.1536 of 5 stars$1.40+0.7%N/A-13.7%$22.34MN/A-1.9420Short Interest ↑Gap UpTAOXSynaptogenix0.1181 of 5 stars$6.21+6.7%N/AN/A$20.30MN/A-0.314Positive NewsETHZFlag Ship AcquisitionN/A$2.67-5.0%N/AN/A$16.97MN/A-0.187IBIOiBio1.8987 of 5 stars$0.81-0.9%$5.00+517.3%-50.9%$15.92M$375K0.00100Short Interest ↑Gap DownNBYNovaBay Pharmaceuticals0.4186 of 5 stars$2.54+42.7%$0.85-66.5%+448.8%$10.37M$9.78M-0.0530Gap UpHigh Trading VolumeMTNBMatinas Biopharma0.1275 of 5 stars$1.83+0.5%N/AN/A$9.31MN/A-0.3830Negative NewsShort Interest ↑Gap DownAEONAEON Biopharma3.1446 of 5 stars$0.74+1.5%$360.00+48,352.2%-98.6%$8.65MN/A4.135News CoveragePositive NewsShort Interest ↓NRBONeuroBo PharmaceuticalsN/A$0.63-2.0%N/A-81.3%$5.46MN/A0.0010AEZSAeterna ZentarisN/A$3.04-4.0%N/A-24.9%$5.45M$2.37M-0.2020CPHIChina PharmaN/A$1.42+2.2%N/A-92.2%$4.63M$4.40M0.00250News CoverageNegative News Related Companies and Tools Related Companies NNVC Alternatives TAOX Alternatives ETHZ Alternatives IBIO Alternatives NBY Alternatives MTNB Alternatives AEON Alternatives NRBO Alternatives AEZS Alternatives CPHI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
